Dietary Lipid Induced Insulin Resistance

Insulin Resistance Clinical Trial

Official title:

Mechanisms of Dietary Lipid Induced Insulin Resistance

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02757560
• Other study ID #: 029
• Status: Active, not recruiting
• Phase: N/A
• Start date: February 2012
• Est. completion date: December 2020

Study information

• Verified date: July 2019
• Source: Phoenix VA Health Care System
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overall goal of the proposal is to use a saturated fatty acid (SFA)- enriched, high fat diet to rapidly induce insulin resistance (IR) to provide insight into underlying proximal mechanisms of reduced insulin signaling. Specifically, investigators will identify the initial changes in metabolite concentrations/or pathway signaling ("pathways" will be used to broadly refer to these mechanism specific measures) and therefore the mechanisms most likely responsible for the development of IR during this high fat nutritional challenge. Investigators have assembled a multidisciplinary team that is versed with dietary studies, fatty acid metabolism, measurement of IR and potential mechanisms and mediators of IR, and has experience working with monocytes and the two tissues, muscle and adipose tissue, that are particularly relevant for understanding the effects of high fat diets on IR.

Description:

In the first aim, investigators will test whether a short-term high SFA-diet induces and increases insulin resistance in participants with normal and abnormal glucose tolerance, respectively, and determine the associated changes in muscle, adipose tissue and inflammatory cell composition, pathway activation and insulin signaling. Investigators will identify changes in specific signal pathways within these tissues and cells that are hypothesized to mediate or modulate insulin action. Primary mechanisms and pathways examined will include local tissue and systemic inflammation, formation of bioactive lipid intermediates, generation of endoplasmic reticulum (ER) stress, and mitochondrial dysfunction/reactive oxygen formation. By performing studies in participants with normal glucose tolerance and in those with abnormal glucose tolerance investigators will also determine whether the extent and mechanisms of insulin resistance vary with initial degrees of glucose intolerance.

In the second aim, to determine if the extent and mechanisms of insulin resistance vary with dietary composition, investigators will determine whether diets of similar caloric content as the SFA-diet, but enriched in monounsaturated fatty acids or carbohydrates, also induce insulin resistance and whether similar or different mechanistic pathways are responsible. Identifying similarities and differences between diets in inflammatory cell and tissue changes and comparing their relationships with peripheral and tissue insulin action will further clarify which cell and tissue events are most closely linked to development of insulin resistance.

In the final aim, to identify the temporal sequence of mechanistic pathways for insulin resistance and the role of cell and tissue cross-talk in these events, investigators will evaluate inflammatory cell, skeletal muscle and adipose tissue composition and pathway changes after acute, subacute, and more chronic dietary challenges in the same individuals. This will also permit assessment of whether repeated dietary challenges create changes in tissues that resemble those found in more chronic and advanced states of insulin resistance.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 300
• Est. completion date: December 2020
• Est. primary completion date: July 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 40 Years to 75 Years

Eligibility

Inclusion Criteria:

• Body mass index (BMI) from 25-35 kg/m2

• normal glucose tolerance (NGT) diagnosis based on fasting glucose value 100mg/dl and 2 hr glucose <140 mg/dl after a standard 75 gm glucose load; impaired fasting glucose (IFG) on fasting glucose value =100 and <126 mg/dl and 2 hr glucose <140 mg/dl; impaired glucose tolerance (IGT) based on 2 hr glucose =140 and <200 mg/dl and a fasting glucose <126 mg/dl

• Fasting triglyceride levels <500 mg/dl

Exclusion Criteria:

• Type 1 or 2 diabetes mellitus or a hemoglobin A1c value = 6.5 mg/dl

• Any diabetes medications in the past month, thiazolidinedione medications in the prior 3 months or prior regular use of insulin

• Use of diets, medications (e.g., steroids, weight loss medications ) or current or planned behavior changes (e.g. acute weight loss, exercise training) that will influence changes in IR

• Creatinine >2.0 mg/dl or other laboratory evidence of significant active disease, including hepatic enzyme elevation >2x normal and anemia, known "Nonalcoholic Fatty Liver Disease", bleeding risk

• Malabsorption of fat or other nutrients, severe lactose intolerance or other significant gastrointestinal or pancreatic problems, or recent history of nausea or vomiting

• Acute bacterial or viral illness or evidence of other active infection in the past 4 weeks

• Cardiovascular event, stable or unstable angina or other major illness in the past 6 months

• Current regular use of anti-inflammatory medications (e.g. salicylates > 1 gm/ day) or antioxidants in excess of a daily multi-vitamin, including supplements (e.g. fish oils)

• Lipid lowering medications must be at a stable dose for at least 2 months prior to participation

• Ethanol consumption more than 4 oz day; more than occasional smoker

• Reproductively active women not on contraceptives

• Known allergies, prior reactions or contraindications to proposed clinical agents (e.g Octreotide)

Related Conditions & MeSH terms

• Insulin Resistance

Intervention

Other:
• SFA diet
SFA versus control diet
• MUFA diet
MUFA versus control diet
• CARB diet
CARB versus control diet

Locations

Country	Name	City	State
United States	Carl T. Hayden VA Medical Center	Phoenix	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Phoenix VA Health Care System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Steady-state plasma glucose (SSPG)	Average plasma glucose concentrations during min 150-180 of the insulin suppression test (IST)	150-180 min
Secondary	Acylcarnitine species	Measured by chromatography electrospray ionization mass spectrometry on plasma and skeletal muscle samples.	Overnight fast, 3-hour post breakfast
Secondary	Diacylglycerol species	Measured on plasma, skeletal muscle and subcutaneous adipose tissue samples.	Overnight fast, 3-hour post breakfast
Secondary	Ceramides species	Measured on plasma, skeletal muscle and subcutaneous adipose tissue samples.	Overnight fast, 3-hour post breakfast
Secondary	Insulin signaling proteins	Measured on skeletal muscle and subcutaneous adipose tissue samples.	Overnight fast, 3-hour post breakfast
Secondary	Inflammation markers	Cytokines and adipokines will be measured in plasma after the diet treatments by ELISA techniques. Mononuclear cells inflammatory gene expression will be measured by real time polymerase chain reaction (RT-PCR). Inflammation will be measured in muscle and adipose tissue by RT-PCR and Western blood analysis.	Overnight fast, 3-hour post breakfast